DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2021 của PharmAust Limited

PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for humans and animals. The company develops drugs for the treatment of various cancers, and viral and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug for the treatment of cancer. PharmAust has completed Phase 1 clinical trials with monepantel in human and dog diagnosed … More with solid tumors, as well as initiated a Phase 2 pilot study in dogs diagnosed with Lymphoma. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.

TÊN CÔNG TY / COMPANY
PharmAust Limited

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
ASX (Australia)

MÃ CHỨNG KHOÁN / TICKER
PAA

KỲ BÁO CÁO
2021

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare

LƯU Ý

  • Xin vui lòng đợi một lát để Báo cáo được tải về, tùy thuộc vào dung lượng của Báo cáo mà thời gian có thể nhanh hoặc chậm.
  • Báo cáo chỉ cho phép xem từ Việt Nam.